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A decade has passed since Pedro and Joseph Brugada (1)
discovered an electrocardiographic (ECG) marker for sud-
den cardiac death in a subset of patients with idiopathic
ventricular fibrillation (VF) characterized by ST-segment
elevation in the right precordial leads (V1 to V3) with a right
bundle branch block pattern. This clinical entity, quickly
recognized as the Brugada syndrome, has drawn widespread
attention from cardiologists, electrophysiologists and ar-
rhythmia scholars throughout the world. We have now
learned that the Brugada syndrome is a familial disease with
an autosomal dominant transmission with incomplete pen-
etrance (2). In addition, the genetic cause of the syndrome
has been identified as a mutation in the cardiac sodium
channel gene, SCN5A (3).
The clinical presentation of the Brugada syndrome is
nocturnal sudden death due to VF occurring mostly in men.
The syndrome is endemic in Southeast Asia and Japan,
where it is also known as sudden unexplained death syn-
drome, and the incidence has been estimated to range
between 5 and 66 events per 100,000 people (2,4). How-
ever, the true incidence may yet to be realized as more
physicians become cognizant of the ECG pattern associated
with the Brugada syndrome and hence, diagnose more
cases.
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It is well known that this ECG pattern can wax and wane
and may be unmasked by sodium channel blockers (5).
However, there are a number of conditions with a similar
ECG pattern similar to that of the Brugada syndrome that
must be considered (6). In other words, not all patients with
the Brugada ECG pattern will have the same high risk of
sudden cardiac death (SCD). More importantly, the in-
crease in the number of asymptomatic patients with the
Brugada ECG pattern poses a therapeutic dilemma to
physicians. While treatment of symptomatic cases has been
studied, there have been, unfortunately, little data to guide
the management of asymptomatic patients.
In this issue of the Journal, Kanda et al. (7) confirm
previous reports that symptomatic patients (aborted SCD or
syncope) are at an inordinate risk of SCD (4,8,9). Of the 34
patients in their study, 15 patients (44%) either died
suddenly or developed VF during the follow-up period
(mean of 38 months). Their observation is similar to that of
a recent article by Brugada et al. (9) showing that 44 of 71
patients (62%) with a history of aborted SCD and 14 of 73
patients (19%) with a history of syncope developed either
SCD or documented VF in the ensuing months (mean
follow-up period of 54 and 26 months, respectively).
When compared to the Brugada et al. (9) findings, the
event rates described by Kanda et al. (7) are slightly lower in
the aborted SCD population but higher in the syncope
population. The small differences in event rates between the
two studies can probably be explained by the longer
follow-up time for the aborted SCD group and shorter
follow-up period for the syncope group in the Brugada et al.
(9) study.
While these two studies are similar in term of the
prognosis of symptomatic patients, they differ with respect
to the prognostic values of the inducibility of sustained
ventricular arrhythmia. The Kanda et al. (7) data suggest
that inducibility of ventricular arrhythmia had no prognostic
value in predicting long-term outcomes because many of
their patients with noninducible, sustained ventricular
tachycardia (VT) developed either SCD or VF. In contrast,
Brugada et al. (9) found that the only variable with
predictive value for SCD or VF was the inducibility of
ventricular arrhythmias during electrophysiological studies.
Examining the differences between the two studies, one
realizes that Brugada et al. (9) have a much larger sample
size. However, Brugada et al. (9) relied on registry infor-
mation from multiple institutions throughout the world
compared to the single institution and somewhat homoge-
neous population from Japan described by Kanda et al. (7).
The number of patients with inducible, sustained ven-
tricular arrhythmias in the Kanda et al. (7) study is slightly
lower than seen by Brugada et al. (9). However, many of the
so-called noninducible patients in the Kanda et al. (7) study
had inducible, nonsustained VT. Whether or not nonsus-
tained VT has any prognostic value remains unclear. How-
ever, if one incorporated nonsustained VT as a positive
electrophysiologic study, Kanda et al. (7) probably would
not be able to conclude that inducibility of ventricular
arrhythmias is not helpful in predicting long-term outcome
because there would be only four patients in their study with
no inducible ventricular arrhythmias.
Although it is not possible to easily reconcile the differ-
ences between these two studies, both data form a consensus
that symptomatic patients with the Brugada ECG pattern
are at very high risk of SCD and should be treated with
implantable cardioverter defibrillators (ICDs). The chal-
lenge is how to treat asymptomatic patients? Should elec-
trophysiologic studies be done to screen for high risk
patients?
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Management of asymptomatic patients becomes a critical
issue because the incidence of asymptomatic Brugada syn-
drome is relatively high, especially in Japan and Asia. For
example, Miyasaka et al. (10) reported that a substantial
number of citizens in the city of Moriguchi, Japan had the
Brugada ECG pattern. The Brugada ECG pattern was
found in 98 of 13,929 of patients and was astonishingly high
(2.14%) in the male subjects. But Miyasaka et al. (10) found
no difference in mortality rate between patients with and
without the Brugada pattern. This is in sharp contrast to the
Brugada et al. (9) finding that 16 of 190 (8%) asymptomatic
patients with Brugada-type ECG patterns had either SCD
or VF during the two-year follow-up period. Again, it is
difficult to compare the two studies because the population
of Moriguchi studied by Miyasaka et al. (10) were older (58
 10 years) than the asymptomatic patients in the Brugada
et al. (9) study (40  16 years). More importantly, subjects
younger than 40 years with no structural heart disease were
excluded from the Miyasaka et al. (10) study because no
ECG examination was available. Therefore, the authors
may have overlooked any high risk patients younger than 40
years. It is also noteworthy that many of the patients with
sudden unexplained death syndrome or Brugada syndrome
tend to be younger than 40 years. Thus, the older popula-
tion with a greater female distribution studied by Miyasaka
et al. (10) excluded the high-risk young male population and
resulted in an overall better prognosis.
Nevertheless, it is clear that the asymptomatic patients
have a much lower risk of sudden cardiac death than
symptomatic patients. The dilemma is that there are many
more asymptomatic patients than symptomatic patients—
and since the ICD is highly effective in preventing death
among symptomatic patients many lives could be potentially
saved by ICD if we could identify the high risk, asymptom-
atic patients as well.
Brugada et al. (9) recommended ICD treatment for
asymptomatic patients whose sustained ventricular arrhyth-
mias could be induced and no ICD treatment for those
without inducible ventricular arrhythmias. This is based on
their finding that 6 of 35 patients (17%) with inducible
ventricular tachyarrhythmias had an arrhythmic event com-
pared to only 1 of 45 patients (2%) with non-inducible
sustained VT. At present, these are the only data available to
guide our treatment approach for asymptomatic patients
with the Brugada-type ECG pattern Unfortunately, data
from the Kanda et al. (7) study are not relevant to asymp-
tomatic patients because they included only symptomatic
patients with aborted SCD or syncope. Further study with
larger populations aiming to determine the value of VT
induction in risk stratification needs to be carried out.
What should the role of electrophysiologic studies be in
patients with Brugada syndrome? For the symptomatic
patients (aborted SCD or syncope), ICD implantation
without electrophysiologic studies is appropriate. It is my
personal preference that it is best to implant a dual-chamber
ICD rather than a single-chamber ICD because atrial
tachyarrhythmias, especially atrial fibrillation and bradycar-
dia, are not infrequent in this population (2). Asymptomatic
patients, however, should undergo electrophysiologic stud-
ies and if inducible, then ICD implantation is appropriate.
Noninducible patients should be followed up regularly and
if they become symptomatic, then ICD treatment is appro-
priate. Additionally, since the Brugada population, espe-
cially in Asia, often has nocturnal VF during sleep, a home
automatic external defibrillator should be considered for
noninducible asymptomatic patients.
Clearly more study is needed to shape our therapeutic
approaches for patients with Brugada syndrome. As more
data become available, the preceding guideline may have to
be modified and improved. Meanwhile, electrophysiologic
studies to determine inducibility of sustained ventricular
arrhythmias remain an important part of risk stratification
for the asymptomatic patient with Brugada syndrome.
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